Genflow Biosciences PLC Announces Holding(s) in Company
Dr Moayyed Al-Qurtas has acquired a significant stake in Genflow Biosciences (GENFF), reaching a 4.45% ownership of voting rights in the company. The threshold crossing occurred on May 9, 2025, and was reported to the company on May 12, 2025. This notification was made in accordance with the UK's Disclosure Guidance and Transparency Rules (DTR5). The acquisition was made through direct ownership of shares, with no financial instruments or indirect holdings involved.
Il dottor Moayyed Al-Qurtas ha acquisito una partecipazione significativa in Genflow Biosciences (GENFF), raggiungendo una quota di proprietà del 4,45% dei diritti di voto nell'azienda. Il superamento della soglia è avvenuto il 9 maggio 2025 ed è stato comunicato all'azienda il 12 maggio 2025. Questa notifica è stata effettuata in conformità con le Regole di Trasparenza e di Comunicazione del Regno Unito (DTR5). L'acquisizione è stata effettuata tramite possesso diretto delle azioni, senza strumenti finanziari o partecipazioni indirette coinvolte.
El Dr. Moayyed Al-Qurtas ha adquirido una participación significativa en Genflow Biosciences (GENFF), alcanzando una propiedad del 4,45% de los derechos de voto en la empresa. El cruce del umbral ocurrió el 9 de mayo de 2025 y fue reportado a la compañía el 12 de mayo de 2025. Esta notificación se realizó conforme a las Reglas de Transparencia y Divulgación del Reino Unido (DTR5). La adquisición se hizo mediante la propiedad directa de acciones, sin instrumentos financieros ni participaciones indirectas involucradas.
모아이예드 알쿠르타스 박사는 Genflow Biosciences(GENFF)의 지분을 상당 부분 확보하여 회사의 의결권 4.45%를 보유하게 되었습니다. 이 지분율 초과는 2025년 5월 9일에 발생했으며, 2025년 5월 12일 회사에 보고되었습니다. 이 통지는 영국의 공시 지침 및 투명성 규칙(DTR5)에 따라 이루어졌습니다. 인수는 금융상품이나 간접 보유 없이 직접 주식 소유를 통해 이루어졌습니다.
Le Dr Moayyed Al-Qurtas a acquis une participation significative dans Genflow Biosciences (GENFF), atteignant une possession de 4,45 % des droits de vote de la société. Le franchissement du seuil a eu lieu le 9 mai 2025 et a été signalé à la société le 12 mai 2025. Cette notification a été faite conformément aux règles de divulgation et de transparence du Royaume-Uni (DTR5). L’acquisition a été réalisée par la détention directe d’actions, sans instruments financiers ni participations indirectes.
Dr. Moayyed Al-Qurtas hat eine bedeutende Beteiligung an Genflow Biosciences (GENFF) erworben und hält nun 4,45 % der Stimmrechte des Unternehmens. Die Überschreitung der Schwelle erfolgte am 9. Mai 2025 und wurde dem Unternehmen am 12. Mai 2025 gemeldet. Diese Mitteilung erfolgte gemäß den britischen Offenlegungs- und Transparenzvorschriften (DTR5). Der Erwerb erfolgte durch direkten Aktienbesitz, ohne finanzielle Instrumente oder indirekte Beteiligungen.
- None.
- None.
Please note that from 22 March 2021, the Standard TR-1 Form should be completed and submitted to the FCA via our Electronic Submission System (ESS) in relation to notifications of voting rights held in issuers whose shares are admitted to trading on UK regulated markets.
Holders of voting rights in issuers whose shares are admitted to trading on UK prescribed markets such as AIM market, can continue to use this form to send their notifications to those issuers. Alternatively, if they wish they can register on ESS to be able to notify to us, produce a TR-1 Form via ESS and submit the downloaded version to issuers with shares admitted to trading on prescribed markets.
More information on how to submit a TR-1 Form via ESS is availablehere
LONDON, UNITED KINGDOM / ACCESS Newswire / May 12, 2025 / TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Genflow Biosciences | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify) iii: | ||||||
3. Details of person subject to the notification obligationiv | ||||||
Name | Dr Moayyed Al-Qurtas | |||||
City and country of registered office (if applicable) | ||||||
4. Full name of shareholder(s) (if different from 3.) v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reachedvi: | 09/05/2025 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 12/05/2025 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |||
Resulting situation on the date on which threshold was crossed or reached | ||||||
Position of previous notification (if applicable) | ||||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
SUBTOTAL 8. A | |||||||||
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Physical or cash Settlementxii | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 | |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | X | |||
Full chain of controlled undertakings through which the voting rights and/or the | ||||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
10.In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional informationxvi | ||||
Place of completion | City of London |
Date of completion | 12/05/2025 |
Notes
iPlease note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link:https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter
iiFull name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.
iiiOther reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.
ivThis should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.
In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:
- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;
- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;
- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;
- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;
- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;
- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;
- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).
vApplicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).
viThe date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.
viiThe total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.
viiiIf the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.
ixIn case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.
xDate of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.
xiIf the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].
xiiIn case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).
xiiiIf the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.
xivThe full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only in this way will the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain by numbering each chain accordingly. Please see the below example:
Name of ultimate controlling person A (chain 1)
Name of controlled undertaking B
Name of controlled undertaking C
Name of ultimate controlling person A (chain 2)
Name of controlled undertaking B
Name of controlled undertaking D
Name of ultimate controlling person A (chain3)
Name of controlled undertaking E
Name of controlled undertaking F
xvThe names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.
xviExample: Correction of a previous notification.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What percentage stake did Dr Moayyed Al-Qurtas acquire in Genflow Biosciences (GENFF)?
When did Dr Al-Qurtas cross the reporting threshold for Genflow Biosciences stock ownership?
Does Dr Al-Qurtas hold any financial instruments or indirect voting rights in GENFF?
Is Genflow Biosciences considered a UK or non-UK issuer for reporting purposes?
